Becton, Dickinson and Company (BDX) has been garnerning considerable attention from the investment community. Analysts have given the company an average rating of a Moderate Buy, and various headlines highlight Becton Dickinson’s strong earning quality. It was also reported that BD has exceeded its Q2 earnings estimates, and that the company has raised its fiscal 2024 Guidance. However, the company also issued warnings about delays in their blood culture product. In terms of acquisitions, Becton Dickinson made a significant move by acquiring Edwards Lifesciences' Critical Care Product Group for $4.2B cash. There are forecasts of a somewhat undervalued stock status for BD, and financials seem to be playing a crucial role in its market performance. According to reports, BD is a new buy stock with strong value and is a recommended hold emanating from its optimistic outlook. Becton Dickinson’s commitment to its 2025 goals is also lauded by analysts. However, criticisms regarding excessive debt and conservative accounting have surfaced. Some investors have even sold their shares in BD. Lastly, the company is expected to provide dividends of $0.95 per share for its Q4 earnings.
Becton Dickinson and BDX News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sun, 11 Aug 2024 16:26:41 GMT -
Rating 6
- Innovation 4
- Information 7
- Rumor -1
